Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > "Griproom" article - 10 signs your company is to be acquired

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Nov 19, 2022 3:37pm

190 Views

Post# 35112929

RE:RE:"Griproom" article - 10 signs your company is to be acquired

Roche & PDAC. The post I was referring to was Noteable and the Morpheus Trial. NCT03193190

This trial certainly reinforces the notion that Roche is a serous PDAC player. I agree that pela could fit, and one would assume it would not take ages to be inserted into Morpheus.

From my lay perspective, I think they should be treating PDAC patients with the biomarkers with Pela right now. Hurry up.

<< Previous

Bullboard Posts

Next >>

How a truck transportation and logistics company leverages acquisitions and technology